Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shicong Tang has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Dong Chen

    Department of Sonography, Peking University Cancer Hospital Yunnan, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China

    9 shared publications
  • Rong Guo

    Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China

    9 shared publications
  • Qing Wang

    Department of Breast Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China

    8 shared publications
  • Dequan Liu

    Department of Breast Surgery, Peking University Cancer Hospital Yunnan, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China

    7 shared publications
  • Rong Guo

    Department of Breast Surgery Third Affiliated Hospital of Kunming Medical University Yunnan Cancer Hospital 650118 Kunming Yunnan China

    7 shared publications
  • Dequan Liu

    Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China

    6 shared publications

Latest Publications

  • Open Access

    The result prediction of fluorescence in situ hybridization for breast cancer patients based on machine learning and deep learning models: a multicenter study

    by Cong Jiang, Dong Chen, Xiao Yu, Shentao Zhang, Yuting Xiu, Ningbin Luo, Jingjing Wu, Xuefang Zhang, Man Chen, Dechun Yang, et al.

    To develop and validate a multicenter ultrasound-based predictive model for fluorescence in situ hybridization (FISH) results in HER2 (2+) breast cancer pa


  • Open Access

    TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers

    by Kang-Liang Lou, Jing-Wen Bai, Hong-Tan Liu, Lin-Ling Lin, Cheng-Xi Li, Yi-Yang Gao, Sheng-Jie Lin, Yi-Fei Pei, Xiao-Long Wei, Yi-Xin Chen, et al.

    In early breast cancer surgery (EBC), free margins significantly decrease local recurrence in breast-conserving surgery (BCS), while metastatic status of sentinel lymph node (SLN) impacts axillary management. However, intraoperative visualization of margins and metastatic SLNs (mSLNs) remains challenging. Here, we report a second-window near-infrared (NIR-II) fluorescence probe by conjugating ICG to TROP2-targeting cyclic peptide (TTP-ICG). Our results showed that TTP-ICG specifically binds to TROP2-expressing cells in vitro and identifies TROP2-positive tumors in vivo. In addition, TTP-ICG enabled efficient intraoperative evaluation of surgical margins and visualization of mSLNs at a submillimeter level in preclinical models. Additionally, we optimized the rapid incubation imaging method (RIIM) by shortening the procedure to less than 8 min, illustrating TTP-ICG’s high performance in distinguishing malignant from normal tissues/fibroadenoma lesions as well as detecting metastatic lymph nodes in a cohort of 59 patients. Thus, this TROP2-targeting probe demonstrates its significance for fluorescence imaging-guided surgery with dual applicability in EBC, providing translational potential for further clinical decision-making.


  • Open Access

    MZB1 at the ER-immunity interface: from antibody folding to disease vulnerability in autoimmunity, inflammation, and cancer

    by Yu Zhang, Wei Yang, Xiaofang Yang, Yuqing Pan, Rong Guo, Dong Chen, Shicong Tang, Xi Zhang

    MZB1 (marginal zone B and B1 cell-specific protein 1) is an endoplasmic reticulum-resident molecular chaperone that is predominantly expressed in marginal zone B cells, B1 cells, plasma cells, and pDCs. Functioning as a co-chaperone of GRP94 and BiP, MZB1 selectively facilitates the proper folding and secretion of immunoglobulin M (IgM) and J-chain-containing immunoglobulin A (IgA) dimers, and maintains the homeostasis of highly secretory cells by upregulating the expression of partner proteins such as BiP/GRP94. This review highlights the emerging role of MZB1 across various pathological conditions. In autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), MZB1 contributes to aberrant autoantibody and cytokine secretion. MZB1 also modulates inflammatory responses in conditions such as colitis and periodontitis by regulating the B cell-skewed inflammatory microenvironment. In oncology, MZB1 is overexpressed in breast cancer (BC), lymphoma, and multiple myeloma (MM), where it is associated with enhanced tumor cell proliferation and poor prognosis. Conversely, in hepatocellular carcinoma (HCC) and gastric cancer (GC), MZB1 is transcriptionally silenced due to promoter hypermethylation. In summary, the tissue-specific expression pattern of MZB1 endows it with potential as both a diagnostic biomarker and therapeutic target, holding significant implications for the exploration of future cancer prognosis and treatment strategies.


  • Open Access

    Single-cell transcriptome sequencing revealing the microenvironment of breast fibroepithelial tumor

    by Tianrun Shu, Jing Wang, Fuying Yang, Dechun Yang, Shengnan Ren, Min Zhao, Yafeng Lv, Ying Song, Hanhui Xie, Xuan Yang, et al.

  • Open Access

    Machine learning model for predicting tertiary lymphoid structures and treatment response in triple-negative breast cancer

    by Yidan Lin, Yushuai Yu, Qing Wang, Kaiyan Huang, Shukai Guo, Jie Zhang, Yihui He, Xin Yu, Jiwen Zhang, Fan Meng, et al.

    This study developed a machine learning model for predicting the presence of tertiary lymphoid structures (TLSs) and treatment response to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC). This multicenter study retrospectively included 697 patients, including the training cohort (n = 137), the TLS validation cohort (n = 63) and the NAT response validation cohorts (n = 560). Five machine learning models were developed to predict the presence of TLSs, and the XGBoost model, which exhibited the best performance, was selected as the radiomics-based TLS (rTLS) predictive model. The rTLS predictive model demonstrated robust predictive performance, including across various patient subgroups. Prognostic analysis showed that the rTLS predictive score was significantly correlated with disease-free survival (DFS) in TNBC receiving NAT, and was identified as a strong independent prognostic factor. Pathomic features further explained the pathological heterogeneity of TNBC with different responses to NAT. Overall, the rTLS predictive model, which accurately predicted the presence of TLSs and treatment response to NAT in TNBC, held promise for future clinical application in formulating personalized strategies for TNBC, ultimately improving prognosis, aiding in individualized patient treatment.


  • Open Access

    Promising future of breast cancer vaccine asking for multidisciplinary collaboration: a literature review

    by Zhanyi Zhang, Mengyuan Li, Lei Zhang, Maohua Wang, Dequan Liu, Shicong Tang, Yuhua Li, Xuedong Fang, Shengnan Ren

    Despite improved efficacy of breast cancer vaccine (BCV) made by multidisciplinary collaboration from fields such as materials science and computer science, clinical translation is still far from satisfactory. Herein, we reviewed the evolution trajectory of BCV and summarized the frontier topics and challenges for achieving successful clinical translation. Our analysis suggests that multi-omics and immunoinformatics are increasingly being used to expand target repertoires, and dedicated vaccine platforms are facilitating precise spatiotemporal co-delivery of epitopes and immune modulators. BCV has evolved towards precise delivery, strong immune properties, and combined therapy. Clinical translation requires the joint efforts of experts in clinical oncology, immunology, pharmacology, materials, and computer science.


  • Open Access

    Prognostic factors analysis and nomogram construction of breast cancer patients lung metastases and bone metastases

    by Mengya Feng, Yihua Kang, Sijia Li, Dechun Yang, Shengnan Ren, Shicong Tang, Dan Mo, Hai Lei


  • Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer

    by Qing Wang, Yushuai Yu, Chenxi Wang, Zirong Jiang, Jialu Li, Xiaofen Li, Xiewei Huang, Ying Song, Zhenhui Li, Shicong Tang, et al.

    Background Tertiary lymphoid structures (TLSs) impact cancer outcomes, including in triple-negative breast cancer (TNBC), where their role in immune modulation during neoadjuvant therapy (NAT) is underexplored. Methods This study employed single-cell RNA sequencing (scRNA-seq), multiplex immunofluorescence (mIF) staining, and radiomic techniques to evaluate TLSs and the tumour microenvironment (TME) in TNBC patient samples before and after NAT. Results The presence of TLSs in TNBC was associated with B-cell maturation and T-cell activation. Compared with TLS-low TNBC, TLS-high TNBC showed significantly greater expression of immunoglobulin family genes (IGHM and IGHG1) in B cells and greater cytotoxicity of neoantigen-specific CD8 + T cells (neoTCR8). Additionally, mIF revealed notable differences between TLSs and the TME in TNBC. Although CD8 + T-cell levels do not predict the NAT response effectively, TLS maturity strongly correlated with better NAT outcomes and prognosis (P < 0.05). An imaging biomarker scoring system was also developed to predict TLS status and NAT efficacy. Conclusion Our results demonstrated changes in TLSs and the TME in TNBC patients post-NAT. These findings confirm the predictive value of mature TLSs (mTLSs) and support the use of personalised immunotherapy based on post-NAT immune characteristics, thereby improving clinical outcomes.


  • Metabolic Heterogeneity and Potential Immunotherapeutic Responses Revealed by Single-Cell Transcriptomics of Breast Cancer

    by Shicong Tang, Qing Wang, Ke Sun, Ying Song, Rui Liu, Xin Tan, Huimeng Li, Yafeng Lv, Fuying Yang, Jiawen Zhao, et al.

    Background Breast cancer (BC) exhibits remarkable heterogeneity. However, the transcriptomic heterogeneity of BC at the single-cell level has not been fully elucidated. Methods We acquired BC samples from 14 patients. Single-cell RNA sequencing (scRNA-seq), bioinformatic analyses, along with immunohistochemistry (IHC) and immunofluorescence (IF) assays were carried out. Results According to the scRNA-seq results, 10 different cell types were identified. We found that Cancer-Associated Fibroblasts (CAFs) exhibited distinct biological functions and may promote resistance to therapy. Metabolic analysis of tumor cells revealed heterogeneity in glycolysis, gluconeogenesis, and fatty acid synthetase reprogramming, which led to chemotherapy resistance. Furthermore, patients with multiple metastases and progression were predicted to benefit from immunotherapy based on a heterogeneity analysis of T cells and tumor cells. Conclusions Our findings provide a comprehensive understanding of the heterogeneity of BC, provide comprehensive insight into the correlation between cancer metabolism and chemotherapy resistance, and enable the prediction of immunotherapy responses based on T-cell heterogeneity.


  • Open Access

    The Correlation Between Essential Amino Acid Tryptophan, Lysine, Phenylalanine and Chemotherapy of Breast Cancer

    by Yafeng Lv, Xuan Yang, Ying Song, Dechun Yang, Kai Zheng, Shaoqiang Zhou, Hanhui Xie, Rong Guo, Shicong Tang

    To investigate the differences in serum tryptophan, lysine, and phenylalanine levels in breast cancer patients, the correlation between the three amino acids with the chemotherapy regimen, and their significance in the clinical diagnosis and treatment of breast cancer. Clinical data were collected from the Department of Breast Surgery at Yunnan Cancer Hospital, encompassing 216 cases from July to December 2020, including 91 healthy individuals, 38 with benign tumors, and 87 with cancer. Amino acid levels were measured using liquid chromatography-tandem mass spectrometry. Statistical analyses, such as the Kruskal-Wallis H-test and Wilcoxon test, were conducted to compare the levels of these amino acids across the healthy group, benign tumor group, and breast cancer group. The χ2 test and Fisher's exact probability method were employed to assess the relationship between amino acid levels and breast cancer stage, grade, and chemotherapy regimen. The results indicated that there were significant differences in serum lysine (H = 36.13, P < .001) and phenylalanine (H = 34.03, P < .001) levels among the three groups. However, tryptophan levels did not show statistically significant variances. Specifically, lysine and phenylalanine levels were significantly different when comparing the healthy group with the breast cancer group and the benign tumor group with the breast cancer group. These differences were not significant when comparing the healthy group with the benign tumor group. Furthermore, there were no statistically significant distinctions observed in lysine (F = 0.836, P > .05) and phenylalanine (F = 1.466, P > .05) levels across different conventional chemotherapy regimens among the breast cancer cases studied. Serum lysine and phenylalanine levels might serve as potential biomarkers for breast cancer, and the choice of chemotherapy regimen is unlikely to impact significant changes in these amino acid levels.